Legacy Private Trust Co. lowered its stake in shares of Teleflex Incorporated (NYSE:TFX) by 3.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 870 shares of the medical technology company’s stock after selling 35 shares during the period. Legacy Private Trust Co.’s holdings in Teleflex were worth $288,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TFX. Geode Capital Management LLC boosted its position in shares of Teleflex by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 410,714 shares of the medical technology company’s stock valued at $106,085,000 after acquiring an additional 17,913 shares during the last quarter. Amundi Pioneer Asset Management Inc. boosted its position in shares of Teleflex by 7.3% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 14,645 shares of the medical technology company’s stock valued at $3,786,000 after acquiring an additional 1,002 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Teleflex by 161.9% during the 4th quarter. Jane Street Group LLC now owns 2,187 shares of the medical technology company’s stock valued at $565,000 after acquiring an additional 1,352 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Teleflex by 0.7% during the 4th quarter. Macquarie Group Ltd. now owns 22,690 shares of the medical technology company’s stock valued at $5,865,000 after acquiring an additional 165 shares during the last quarter. Finally, FMR LLC boosted its position in shares of Teleflex by 1.0% during the 4th quarter. FMR LLC now owns 1,357,213 shares of the medical technology company’s stock valued at $350,812,000 after acquiring an additional 13,908 shares during the last quarter. 91.46% of the stock is currently owned by institutional investors.
A number of analysts recently issued reports on the company. Wells Fargo & Co downgraded Dave & Buster’s Entertainment from an “outperform” rating to a “market perform” rating and set a $48.00 price target for the company. in a research report on Tuesday, June 11th. Zacks Investment Research downgraded Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Barclays raised their price target on Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a research report on Monday, April 15th. Morgan Stanley lowered their price target on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, July 16th. Finally, Needham & Company LLC raised their price target on CoStar Group from $500.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $333.75.
Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.17 by $0.07. The company had revenue of $613.60 million during the quarter, compared to the consensus estimate of $608.27 million. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. Teleflex’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the company earned $2.15 earnings per share. On average, sell-side analysts anticipate that Teleflex Incorporated will post 11.05 EPS for the current year.
In other Teleflex news, VP Cameron P. Hicks sold 1,500 shares of the stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $298.14, for a total value of $447,210.00. Following the sale, the vice president now owns 6,876 shares in the company, valued at $2,050,010.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $343.28, for a total value of $68,656.00. Following the completion of the sale, the director now owns 936 shares in the company, valued at approximately $321,310.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,949 shares of company stock worth $17,239,052. Insiders own 2.36% of the company’s stock.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Article: What is a Fiduciary?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.